Drugs

Andrea Apolo: Phase 1 study of Cabozantinib, Nivolumab, and Ipilimumab for genitourinary tumours

Photo from Andrea Apolo/X

Jul 5, 2024, 15:03

Andrea Apolo: Phase 1 study of Cabozantinib, Nivolumab, and Ipilimumab for genitourinary tumours

Andrea Apolo, Chief of Bladder Cancer Section Genitourinary Malignancies Branch Center for Cancer Research at NCI, shared on X:

“Cabozantinib/Nivolumab and Cabozantinib/Nivolumab/Ipilimumab have shown promising efficacy and safety in patients with metastatic urothelial carcinoma, metastatic renal cell carcinoma and rare GU tumors in a dose-escalation phase I study.”

Andrea Apolo

Additional information.
Source: Andrea Apolo/X

Andrea Apolo Cabozantinib cancer ipilimumab metastatic renal cell carcinoma nivolumab OncoDaily Oncology urothelial carcinoma

FDA Priority Review Granted for TAR-200 After 82% Complete Response in BCG-Unresponsive Bladder Cancer

Paolo Tarantino: AACR Journals' Power Move for Reviewers

Best Immunotherapy Highlights from ESMO TAT ASIA 2025 You Shouldn't Miss

Oncologist Near Me – Nagashree Seetharamu: A Journey of Healing, Mentorship, and Leadership

Mohit Manrao: FDA Grants Priority Review for sBLA in Resectable Early-Stage Gastric and GEJ Cancers

Special Coverage

Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
ESMO 2024 Congress
September 13-17, 2024
ASCO Annual Meeting
May 30 - June 4, 2024
Yvonne Award 2024
May 31, 2024
OncoThon 2024, Online
Feb. 15, 2024
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023

Facebook

Youtube

Insight

Aug 2, 2025, 00:36

Elizabeth Smyth: Review on a Key Emerging Biomarker in Gastric and Gastroesophageal Cancer

Blog

Aug 2, 2025, 00:00

Maryam Lustberg: Discussing PCPs vs Oncologists

Blog

Aug 1, 2025, 19:24

Oliver Bogler: What Reviewers Hate to See

Science

Aug 1, 2025, 19:18

Wolfgang Miesbach: How Far Will AI Reach? Stanford's Virtual Lab's Breakthrough

Blog

Aug 1, 2025, 19:14

The Impact Your Support Makes in the Fight Against Cancer - NFCR

Blog

Aug 1, 2025, 19:10

YARN: An Ambitious, Bold and Promising EU-Funded Initiative - Youth Cancer Europe

Science

Aug 1, 2025, 19:04

Karen Knudsen: Science in Action - Men with Advanced Prostate Cancer Benefit

Positive

Aug 1, 2025, 18:57

Two Behaviour Change Campaigns Are the Finalists at 2025 Effie Awards - Cancer Institute NSW

Career

Aug 1, 2025, 18:52

Brian A. Walker Joins Sylvester Myeloma Institute - Sylvester Comprehensive Cancer Center

Blog

Aug 1, 2025, 18:42

Identifying and Preparing Eligible Patients for Screening with Confidence - ACS NLCRT

Insight

Aug 1, 2025, 18:37

Miguel Bronchud: SEOM Has Published the 2025 Medical Oncology Research Dossier in English

Blog

Aug 1, 2025, 18:32

Sharon Kapambwe: Representing WHO in Uzbekistan